Daratumumab in multiple myeloma

The Lancet

Volumn 387, Issue 10027, 2016, Pages 1490-1492

  Rajkumar, S Vincent ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALKYLATING AGENT; ANTHRACYCLINE; BORTEZOMIB; CARFILZOMIB; DARATUMUMAB; DEXAMETHASONE; DINACICLIB; ELOTUZUMAB; FILANESIB; ISATUXIMAB; IXAZOMIB; LENALIDOMIDE; LGH 447; OPROZMIB; PANOBINOSTAT; POMALIDOMIDE; PROTEASOME INHIBITOR; PROTEIN KINASE INHIBITOR; RITUXIMAB; SALINOSPORAMIDE A; THALIDOMIDE; UNCLASSIFIED DRUG; VENETOCLAX; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY;

AUTOLOGOUS STEM CELL TRANSPLANTATION; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; HUMAN; MINIMAL RESIDUAL DISEASE; MONOTHERAPY; MULTICENTER STUDY (TOPIC); MULTIPLE MYELOMA; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SHORT SURVEY; TREATMENT OUTCOME; FEMALE; MALE; TUMOR RECURRENCE;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; FEMALE; HUMANS; MALE; MULTIPLE MYELOMA; NEOPLASM RECURRENCE, LOCAL;

EID: 84953234682     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(15)01226-X     Document Type: Note

References (13)

1. MV Abola, V Prasad The use of superlatives in cancer research JAMA Oncol 2015 10.1001/jamaoncol.2015.3931 published online Oct 29
2. HM Lokhorst, T Plesner, JP Laubach et al. Targeting CD38 with daratumumab monotherapy in multiple myeloma N Engl J Med 373 2015 1207 1219
3. S Lonial, BM Weiss, SZ Usmani et al. Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial Lancet 2016 published online Jan 6. http://dx.doi.org/10.1016/S0140-6736(15)01120-4
4. SK Kumar, A Dispenzieri, MQ Lacy et al. Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients Leukemia 28 2014 1122 1128
5. PG Richardson, B Barlogie, J Berenson et al. A phase 2 study of bortezomib in relapsed, refractory myeloma N Engl J Med 348 2003 2609 2617
6. P Richardson, S Jagannath, M Hussein et al. Safety and efficacy of single-agent lenalidomide in patients with relapsed and refractory multiple myeloma Blood 114 2009 772 778
7. DS Siegel, T Martin, M Wang et al. A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma Blood 120 2012 2817 2825
8. PG Richardson, DS Siegel, R Vij et al. Pomalidomide alone or in combination with low-dose dexamethasone in relapsed and refractory multiple myeloma: a randomized phase 2 study Blood 123 2014 1826 1832
9. S Lonial, M Dimopoulos, A Palumbo et al. Elotuzumab therapy for relapsed or refractory multiple myeloma N Engl J Med 373 2015 621 631
10. P Moreau, M-V Mateos, J Bladé et al. An open-label, multicenter, phase 1b study of daratumumab in combination with backbone regimens in patients with multiple myeloma Blood 124 2014 176 (abstr).
11. M Attal, V Lauwers-Cances, C Hulin et al. Autologous transplantation for multiple myeloma in the era of new drugs: a phase III study of the Intergroupe Francophone Du Myelome (IFM/DFCI 2009 Trial) ASH Annual Meeting Abstracts 126 2015 A391 (abstr).
12. AM Rajan, SV Rajkumar Interpretation of cytogenetic results in multiple myeloma for clinical practice Blood Cancer J 5 2015 e365
13. SV Rajkumar Myeloma today: disease definitions and treatment advances Am J Hematol 2015 10.1002/ajh.24236 published online Nov 13